TLX1 N logo

Telix Pharmaceuticals LimitedBMV:TLX1 N Stock Report

Market Cap Mex$57.5b
Share Price
n/a
1Yn/a
7D0%
Portfolio Value
​
View

Telix Pharmaceuticals Limited

BMV:TLX1 N Stock Report

Market Cap: Mex$57.5b

Telix Pharmaceuticals (TLX1 N) Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. More details

TLX1 N fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance1/6
Financial Health2/6
Dividends0/6

Rewards

Trading at 67.2% below our estimate of its fair value

Earnings are forecast to grow 46.45% per year

Risk Analysis

Shares are highly illiquid

Debt is not well covered by operating cash flow

Large one-off items impacting financial results

Profit margins (1.6%) are lower than last year (7.6%)


TLX1 N Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW481,446 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
481,446 investors already sharing narratives
View all narratives

Telix Pharmaceuticals Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Telix Pharmaceuticals
Historical stock prices
Current Share PriceAU$302.55
52 Week HighAU$302.55
52 Week LowAU$302.55
Beta2.27
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO0%

Recent News & Updates

Recent updates

Shareholder Returns

TLX1 NMX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how TLX1 N performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how TLX1 N performed against the MX Market.

Price Volatility

Is TLX1 N's price volatile compared to industry and market?
TLX1 N volatility
TLX1 N Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: TLX1 N's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine TLX1 N's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015423Chris Behrenbruchtelixpharma.com

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.

Telix Pharmaceuticals Limited Fundamentals Summary

How do Telix Pharmaceuticals's earnings and revenue compare to its market cap?
TLX1 N fundamental statistics
Market capMex$57.55b
Earnings (TTM)Mex$201.86m
Revenue (TTM)Mex$12.36b
297.5x
P/E Ratio
4.9x
P/S Ratio

Is TLX1 N overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TLX1 N income statement (TTM)
RevenueUS$664.23m
Cost of RevenueUS$305.95m
Gross ProfitUS$358.28m
Other ExpensesUS$347.43m
EarningsUS$10.84m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.032
Gross Margin53.94%
Net Profit Margin1.63%
Debt/Equity Ratio91.0%

How did TLX1 N perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/10 09:15
End of Day Share Price 2025/06/13 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Telix Pharmaceuticals Limited is covered by 23 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Melissa BensonBarrenjoey Markets Pty Limited
John HesterBell Potter
Shane StoreyCanaccord Genuity